Immune checkpoint inhibitors revolutionize cancer treatment by harnessing the immune system’s ability to target tumor cells more effectively than conventional chemotherapy. Notably, ICIs exhibit superior tolerability profiles in elderly patients, a cohort traditionally vulnerable to the toxicities of cytotoxic agents. Nonetheless, the clinical application in the elderly is hampered by their underrepresentation in pivotal clinical trials, creating critical gaps in understanding the spectrum and severity of immune-related adverse events (irAEs) linked to ICIs, particularly as they may vary between different tumor types.

Addressing this knowledge void, a pioneering retrospective observational study spearheaded by Peking University Cancer Hospital analyzed real-world data from 407 elderly patients aged 70 years and above, all having undergone at least two cycles of ICI therapy. This cohort included 261 patients with gastrointestinal tumors and 146 with lung cancer, enrolled between January 2016 and February 2022. By applying a sophisticated 2:1 propensity score matching approach, the investigators meticulously balanced covariates such as sex, smoking history, Eastern Cooperative Oncology Group (ECOG) performance status, and concomitant treatment modalities, culminating in two well-matched groups: 197 elderly patients with GI tumors and 133 with lung cancer.

The study’s primary endpoint focused on the incidence of any-grade irAEs, which were systematically classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, while a secondary analysis explored organ-specific toxicity profiles. These rigorous methodologies represent a significant advancement in carefully delineating the nuanced safety landscape of ICIs in elderly populations afflicted with distinct tumor types, an area previously obscured by heterogeneous clinical trial data.

Intriguingly, the results revealed a tangible disparity in the incidence of immune-related toxicities between the two cohorts. The overall irAE occurrence was 52.6% across the study population, yet lung cancer patients exhibited a notably higher incidence at 61.0%, compared to 47.9% in GI tumor patients—a statistically significant difference underscored by a p-value of 0.013. This trend persisted post-propensity score matching, with lung cancer group irAEs slightly higher (61.7% vs. 50.8%, though just shy of statistical significance at p=0.056), and a pronounced difference in mild-to-moderate (grade 1-2) irAEs favoring lung cancer patients (52.6% vs. 37.1%, p=0.006).

Diving deeper into the organ-specific irAEs, the study uncovered distinctive patterns reflective of tumor biology and host immune interaction. Cutaneous toxicities emerged as the most prevalent irAE, affecting 23.8% of the entire cohort, but displayed a significant predilection for GI tumor patients, with a 28.7% incidence relative to 15.1% among lung cancer patients (p=0.002). Conversely, thyroid dysfunction—characterized by autoimmune thyroiditis or hypothyroidism—surfaced as a prominent adverse event within the lung cancer group, occurring in 28.1% of patients versus 11.9% in those with GI tumors (p < 0.001). Other organ systems, including hepatobiliary toxicity, cytopenias, and pneumonitis, showed no statistically significant differences between the groups, suggesting a degree of tumor-specific immune modulation confined to particular organ toxicities.

These findings illuminate a complex interplay between tumor microenvironment heterogeneity and systemic immune responses modulated by ICIs, which may be further influenced by gut microbiota compositions, especially relevant in GI cancers. The gut microbiome’s modulatory role in immune homeostasis and response to checkpoint blockade introduces a mechanistic hypothesis for the observed differential patterns of irAEs. Understanding such interactions could pave the way for novel predictive biomarkers and tailored prophylactic approaches to manage toxicity profiles across diverse oncologic populations.

Importantly, this research stands as the inaugural large-scale real-world investigation to dissect tumor-specific immune toxicities in an elderly cohort, filling a crucial evidence gap left by randomized controlled trials. The clinical implications are profound: practitioners should adopt vigilant monitoring protocols for thyroid dysfunction in elderly lung cancer patients receiving ICIs and simultaneously be alert for cutaneous irAEs in those battling GI tumors. Tailoring surveillance and management strategies according to tumor type could mitigate adverse effects, enhance patient quality of life, and potentially improve treatment adherence.

While these insights herald a new frontier in geriatric oncology, the study’s limitations must be acknowledged. Being a single-center retrospective analysis confines the generalizability of the findings, and the absence of longitudinal data correlating irAEs with therapeutic efficacy leaves critical questions unanswered. Future multicenter prospective studies integrating robust biomarker analyses and longitudinal follow-up are indispensable to validate and expand upon these foundational observations.

Led by Dr. Yuyan Wang, a distinguished thoracic oncologist at Peking University Cancer Hospital, this study underscores an era where clinical research is increasingly responsive to the nuances of elderly cancer care. Dr. Wang’s expertise in thoracic oncology and her research into tumor microenvironment dynamics and molecular resistance mechanisms have been instrumental in shaping this pioneering investigation. Supported by multiple institutional and national grants, the collaborative endeavor reflects a commitment to addressing the unmet needs of an aging oncologic population.

Collectively, these findings advance our understanding of immunotherapy’s safety profile among elderly patients with lung and GI cancers, reinforcing the necessity for tumor-specific and patient-centered approaches. They evoke critical questions about the immunobiology underpinning differential irAE manifestations and herald an opportunity for precision medicine to extend beyond efficacy into toxicity management. As the medical community grapples with rising cancer burdens in the elderly, such research offers hope for improved outcomes through personalized, immune-guided treatment strategies.

In summary, this landmark real-world study elucidates the heterogeneous landscape of immune-related adverse events in elderly patients treated with ICIs for gastrointestinal and lung cancers. The discernible variation in both incidence and organ-specific toxicity emphasizes the importance of tumor biology in shaping immune responses and adverse event profiles. Enhanced surveillance tailored to tumor site—especially for thyroid dysfunction in lung cancer and skin toxicities in GI cancers—may optimize immunotherapy’s risk-benefit balance and usher in refined standards of care for an increasingly vulnerable patient population.

Subject of Research: People

Article Title: Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study

News Publication Date: 3-Apr-2026

Web References: DOI link

References: DOI: 10.1097/CM9.0000000000004069

Image Credits: Chinese Medical Journal

Keywords: Immune checkpoint inhibitors, elderly cancer patients, gastrointestinal cancer, lung cancer, immune-related adverse events, toxicity profiles, tumor microenvironment, propensity score matching, thyroid dysfunction, skin toxicity, real-world study, immunotherapy

Stage III NSCLC represents a particularly challenging clinical scenario characterized by locally advanced tumors often deemed unresectable, with a high risk of both local failure and distant metastasis. Conventional treatment strategies have typically relied on concurrent chemo-radiotherapy, which, despite representing the current standard of care, yields suboptimal long-term survival outcomes. The APOLO trial builds upon significant advancements in immunotherapy, particularly immune checkpoint inhibitors, which have revolutionized cancer treatment over the past decade by empowering the patient’s own immune system to recognize and eradicate malignant cells.

The rationale behind the APOLO regimen lies in the synergistic potential of combining chemotherapy and immunotherapy as induction treatment, designed to debulk tumor burden and prime the immune microenvironment before administering definitive chemo-radiotherapy. This multimodal sequence is then followed by maintenance immunotherapy to sustain immune surveillance and suppress residual disease. Preliminary evidence suggested that such an approach could much more effectively overcome the tumor microenvironment’s immunosuppressive barriers, thereby enhancing durable responses and long-term survival.

In this tightly designed phase 2 study, patients with stage III NSCLC first received induction chemo-immunotherapy, which typically involved platinum-based chemotherapy in combination with an immune checkpoint inhibitor targeting the PD-1/PD-L1 axis. The goal was to exploit chemotherapy’s immunomodulatory effects—such as increasing tumor antigen release and enhancing dendritic cell maturation—while simultaneously activating T-cell mediated immunity via checkpoint blockade. Following this induction phase, subjects underwent standard concurrent chemotherapy with thoracic radiotherapy, aiming to eradicate the primary tumor and involved lymph nodes.

What sets the APOLO trial apart is its strategic incorporation of maintenance immunotherapy immediately after completion of chemo-radiotherapy. This continuous immune awakening intends to maintain cytotoxic T cell activity over time, reducing risk of both local relapse and distant metastasis. The trial meticulously monitored efficacy parameters such as progression-free survival, overall survival, and objective response rates, alongside thorough safety profiling to gauge tolerability of this intensive combined regimen.

The findings from the APOLO trial are highly encouraging—participants experienced notably improved response rates and prolonged progression-free intervals compared to historical controls receiving chemo-radiotherapy alone. Remarkably, the integration of immunotherapy in both induction and maintenance phases was well-tolerated, with adverse events consistent with known profiles of checkpoint inhibitors and chemotherapy agents. Importantly, no new safety signals emerged, highlighting the feasibility of this complex therapeutic strategy in a clinical setting.

Mechanistically, the study provides incisive insights into the tumor immune microenvironment dynamics. Analysis revealed enhanced infiltration of cytotoxic CD8+ T cells and reduction of immunosuppressive regulatory T cells following induction therapy, suggesting effective immune priming. Moreover, radiotherapy appeared to synergize by inducing immunogenic cell death, releasing tumor neoantigens that further stimulate the adaptive immune system, thus cloaking the residual tumor in an immunologically ‘hot’ milieu conducive to sustained checkpoint blockade efficacy.

This concept of ‘priming and boosting’ the immune response through sequential chemo-immunotherapy followed by definitive chemo-radiotherapy and maintenance immunotherapy represents a paradigm shift in managing locally advanced lung cancer. By leveraging the complementary mechanisms of each therapeutic component, the APOLO trial advances the notion that timing and sequencing are critical to optimizing anti-tumor immunity and achieving durable tumor control.

The implications extend beyond lung cancer, as this multimodal regimen challenges conventional silos of medical oncology, radiation oncology, and immunotherapy. It underscores the necessity of integrating personalized immunologic profiling and biomarker-driven patient selection to identify those most likely to benefit from such intensively tailored treatments. In addition, APOLO’s blueprint raises provocative questions about combining novel agents, such as next-generation immune modulators or targeted therapies, at various stages of the regimen for further enhancements.

From a clinical standpoint, APOLO offers hope to patients facing stage III NSCLC, a disease entity long associated with dismal outcomes and high morbidity. The prospect of a more effective, yet tolerable treatment algorithm aligns with the urgent need for strategies that extend survival, preserve quality of life, and ultimately increase the number of cures. Furthermore, ongoing follow-up will be essential to define long-term survival benefits, late toxicity manifestations, and potential resistance mechanisms emerging from this complex therapeutic interplay.

In conclusion, the phase 2 APOLO trial represents a seminal advancement in precision oncology for stage III NSCLC. By demonstrating the safety and enhanced efficacy of an induction chemo-immunotherapy strategy followed by chemo-radiotherapy and immunotherapy maintenance, this study offers a robust framework for future large-scale trials and potential changes in treatment guidelines. It exemplifies the tremendous promise of harnessing the immune system’s power alongside conventional modalities to rewrite the narrative of a deadly disease.

As the oncology community eagerly anticipates the results of ongoing and future phase 3 studies validating APOLO’s findings, the integration of immunotherapy into early treatment phases of lung cancer heralds a new era of innovation and hope. The intricate choreography between chemotherapy, radiotherapy, and immunotherapy invites a rethinking of how multifaceted cancer treatments can be optimized to outsmart tumor adaptation and immune evasion. Ultimately, APOLO charts a course toward transformation—turning the tide against stage III NSCLC and illuminating pathways forward for other malignancies driven by immune resistance.

Subject of Research: Treatment of stage III non-small cell lung cancer (NSCLC) using a combined chemo-immunotherapy and chemo-radiotherapy approach followed by immunotherapy maintenance.

Article Title: Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Article References:
Provencio, M., Campos, B., Guirado, M. et al. Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. Nat Commun 16, 10124 (2025). https://doi.org/10.1038/s41467-025-66097-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-66097-w

Immune checkpoint inhibitors have long been hailed as revolutionary in oncology, empowering the immune system to recognize and destroy cancer cells. Central to this mechanism is the PD-1 receptor on immune cells and its ligand PD-L1 on tumor cells. By blocking this interaction, anti-PD-1 drugs release the brakes on immune responses, promoting tumor eradication. Yet, a significant subset of NSCLC patients derives little benefit from such therapies, highlighting the urgent need to decode the molecular underpinnings of immunotherapy resistance.

KIF20A emerged from an integrative bioinformatics approach as a hub gene intricately linked with resistance phenotypes. Known primarily as a cell cycle regulator associated with chemotherapy resistance, KIF20A’s role in tumor immunity had remained elusive until now. Utilizing datasets from TCGA and GEO, the research team systematically pinpointed KIF20A’s aberrant overexpression in NSCLC tumors compared to adjacent normal tissues, a revelation that set the stage for deeper clinical inquiry.

The study’s clinical arm incorporated a cohort of 106 NSCLC patients undergoing anti-PD-1 treatment, with KIF20A expression quantified through rigorous immunohistochemical (IHC) analyses. The findings were compelling: over 63% of tumor samples exhibited high KIF20A protein levels versus a mere 13.2% in normal tissue counterparts. Moreover, elevated KIF20A correlated strongly with aggressive clinicopathological features including lymph node metastasis, poor differentiation, and advanced tumor stages, reinforcing its prognostic significance.

Delving into the tumor microenvironment (TME), the researchers deployed multiplex immunofluorescence (mIHC) to scrutinize PD-L1 expression patterns in tandem with KIF20A levels. A striking inverse relationship emerged—tumors with high KIF20A expression manifested significantly diminished densities of PD-L1-positive tumor cells. This downregulation of PD-L1 in KIF20A-overexpressing tumors suggests a sophisticated tumor adaptive mechanism, potentially undermining the tumor’s visibility to PD-1 targeted therapies and thus fueling primary resistance.

Survival analyses cemented the clinical implications of these molecular dynamics. Patients harboring tumors with high KIF20A expression experienced markedly shorter overall survival post-immunotherapy initiation. The hazard ratio of 3.40 indicates a more than threefold increased risk of mortality compared to patients with lower KIF20A expression, underscoring the biomarker’s powerful prognostic capability. Even more concerning was the synergistic effect observed in the subgroup with combined high KIF20A and low PD-L1 expression, where survival outcomes plummeted further, embodying a particularly resistant and aggressive tumor phenotype.

Mechanistically, the study advances the concept that KIF20A may drive anti-PD-1 resistance by actively repressing PD-L1 expression, thereby rendering immunotherapeutic blockade ineffective. This insight challenges the traditional understanding that PD-L1 presence is invariably a marker of immune evasion, revealing a complex interplay where its suppression can also underpin resistance through immune escape pathways yet to be fully elucidated.

From a therapeutic standpoint, KIF20A’s identification as a resistance driver holds tremendous promise. Targeting KIF20A directly or modulating its downstream effects could restore PD-L1 expression levels or circumvent PD-L1-independent escape mechanisms, thus sensitizing tumors to immune checkpoint blockade. Moreover, integrating KIF20A status into clinical decision-making may refine patient selection for immunotherapy, sparing non-responders from unwarranted side effects and guiding them towards alternative modalities.

The integration of advanced bioinformatics with meticulous clinical validation exemplifies the power of translational oncology research. By leveraging large-scale genomic datasets and sophisticated imaging modalities, the investigators have constructed a compelling narrative that bridges molecular biology with tangible clinical outcomes, enriching the collective understanding of NSCLC immunoresistance.

Beyond its immediate application, this study prompts a reevaluation of tumor immune evasion paradigms. The counterintuitive finding that PD-L1 downregulation via KIF20A elevates therapeutic resistance demands further scrutiny into the intricacies of the tumor-immune dialogue, potentially revealing novel checkpoints and escape mechanisms exploitable for treatment.

Future research trajectories may focus on dissecting the signaling networks connecting KIF20A to PD-L1 transcriptional and post-translational regulation, as well as exploring the broader impact of KIF20A on immune cell infiltrates within the tumor milieu. Such insights could unveil multifaceted strategies to dismantle the immunosuppressive fortress constructed by resistant tumors.

In essence, this seminal investigation not only identifies KIF20A as a pivotal molecule orchestrating resistance to anti-PD-1 therapy in NSCLC, but also positions it as a dual biomarker and therapeutic target. The KIF20A/PD-L1 signature provides a robust framework for risk stratification and personalized medicine, moving the needle closer to overcoming the immunotherapy resistance frontier that has long stalled progress in lung cancer treatment.

As immuno-oncology continues its rapid ascent, the revelation of KIF20A’s role represents a critical piece of the complex puzzle, offering hope for more durable responses and improved survival for patients grappling with NSCLC. Harnessing this knowledge could ultimately translate into next-generation therapies capable of outsmarting tumor escape strategies and achieving sustained remission.

The study’s multidisciplinary approach, encompassing computational analysis, pathological assessment, and survival modeling, showcases the future of cancer research—integrative, dynamic, and patient-centered. Its findings reinforce the imperative of personalized medicine and herald a new chapter in the battle against one of the deadliest malignancies known.

This fresh perspective on resistance mechanisms also highlights the necessity of continual biomarker discovery and validation in clinical cohorts to ensure that treatment paradigms evolve synchronous with emerging molecular insights. KIF20A stands out as a beacon in this endeavor, illuminating paths toward improved diagnostic accuracy and enhanced therapeutic precision.

In conclusion, the discovery of KIF20A’s capacity to drive anti-PD-1 resistance via PD-L1 downregulation in NSCLC enriches the scientific community’s understanding of tumor immune evasion and lays critical groundwork for innovative clinical applications. It exemplifies the profound impact that molecular characterization can exert on shaping the future of cancer therapeutics.

Subject of Research: The role of KIF20A in driving primary resistance to anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) through modulation of PD-L1 expression and its implications for tumor microenvironment and patient prognosis.

Article Title: KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis

Article References:
Su, T., Li, L., Jing, C. et al. KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis. BMC Cancer 25, 1794 (2025). https://doi.org/10.1186/s12885-025-15221-6

Image Credits: Scienmag.com

DOI: 20 November 2025

The study focuses on the effects of immune checkpoint inhibitors, a class of drugs that have revolutionized oncology by unleashing the immune system’s ability to fight cancer. These drugs target specific proteins on immune cells and cancer cells, effectively enhancing the immune response against tumor growth. When combined with chemoradiotherapy, a simultaneous application of chemotherapy and radiation, the implications are profound. The study’s findings suggest that this combination alters traditional patterns of cancer recurrence and progression, which could reshape treatment protocols moving forward.

Researchers meticulously analyzed clinical data from patients who received simultaneous chemoradiotherapy and immune checkpoint inhibitors. They discovered that the treatment greatly influenced where and how the cancer recurred. Unlike previous models predicting cancer failure based on the tumor’s initial size and location, this new data shows a nuanced array of recurrence patterns that demand further exploration to understand their biological underpinnings. By identifying these shifts in tumor behavior, medical practitioners can tailor follow-up strategies and monitoring efforts accordingly.

The implications of these findings are vast and multifaceted. First, the alteration of recurrence patterns means that physicians must reevaluate their criteria for assessing a patient’s continued risk post-therapy. In essence, the old adage of “where there’s smoke, there’s fire” may not apply as cleanly to this new treatment landscape. New guidelines may well emerge from these data, advocating for innovative imaging studies and monitoring strategies that account for the unique recurrences associated with this combined approach.

Notably, the study explored not just the location but also the nature of relapsed tumors, examining whether they displayed different genetic or histological characteristics. The researchers discovered remarkable heterogeneity among the relapse cases, indicating that the biology driving earlier tumors might diverge significantly as a consequence of treatment. Such insights underscore the dynamic nature of tumor evolution in response to therapies and highlight the potential for developing personalized treatment plans based on individual tumor behavior.

Moreover, an important angle to the study was the investigation into the immune environment of tumors following combined therapy. The immune profile was markedly different post-treatment, suggesting that the chemotherapy and radiation had altered the tumor microenvironment in a way that affected immune cell infiltration and activity. This observation raises pivotal questions about how these external changes to the tumor habitat could be harnessed to improve patient outcomes further and potentially how to combine other modalities, such as targeted therapies, to enhance the immune response.

The researchers also delved into the timing and sequencing of treatments. Traditionally, chemoradiotherapy has been administered either sequentially or concurrently without a clear understanding of how these modalities could be maximized when administered alongside immune checkpoint inhibitors. The study’s findings suggest that the treatment sequence may influence the immune response and the likelihood of tumor recurrence, opening the door for innovative clinical trials designed to test the optimal strategies. Future studies will likely need to focus on this aspect to delineate the best approaches that give patients the most significant advantage in their fight against NSCLC.

Patient selection also emerged as a crucial point of discussion. The findings suggest that not all patients with inoperable stage III NSCLC may benefit similarly from the inclusion of immune checkpoint inhibitors. The study indicated that various biomarker profiles could predict responsiveness to this combination therapy, reinforcing the idea that personalized medicine is essential in oncology. Identifying which specific patients would reap the most benefit from this treatment paradigm could lead to better-tailored interventions, maximizing efficacy while minimizing unnecessary exposure to potent therapies.

Furthermore, the study considered the adverse effects associated with this combination therapy. Combining immune checkpoint inhibition with chemoradiotherapy does not come without its challenges; side effects can be compounded, leading to increased morbidity rates. The understanding of how these new recurrence patterns relate to adverse effects will be critical in informing safer therapeutic practices. Clinicians will need to navigate these potential pitfalls carefully to maintain a balance between maximizing treatment benefits and minimizing harmful effects.

As we stand on the cusp of this new phase in lung cancer treatment, it is evident that further research is critically needed. The current study serves as a stepping stone toward understanding the complex interplay between various treatment modalities and tumor behavior. The quest for knowledge will not only advance the scientific community’s understanding of tumor resistance and recurrence but also fundamentally improve patient care, survival outcomes, and quality of life.

In conclusion, this pivotal research highlights the importance of integrating immune checkpoint inhibitors into the treatment landscape for inoperable stage III NSCLC patients. The study’s findings prompt a reevaluation of traditional paradigms surrounding cancer recurrence and progression following treatments, advocating for a more nuanced approach to patient management. As we delve deeper into the molecular mechanisms underpinning these changes, we strengthen the path toward a future where personalization in cancer care is the norm rather than the exception.

The integration of immunotherapy into conventional treatment pathways represents a paradigm shift in oncology. Researchers and clinicians are encouraged to consider the broader implications of these findings, particularly how they inform current treatment protocols and future research ventures. As we move forward, there lies an extraordinary opportunity to innovate and refine therapeutic strategies that truly harness the power of the immune system in the fight against cancer.

These groundbreaking insights open new avenues for research, treatment development, and patient care, setting the stage for a more promising future for individuals burdened by inoperable stage III non-small cell lung cancer. As we continue to tease apart the complexities of cancer treatment, it is clear that a collaborative, multidisciplinary approach will be critical in conquering this formidable disease.

Subject of Research: Immune checkpoint inhibition and chemoradiotherapy patterns in inoperable stage III non-small cell lung cancer.

Article Title: Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.

Article References:

Taugner, J., Stamer, S., Hofstetter, K. et al. Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.
J Cancer Res Clin Oncol 151, 313 (2025). https://doi.org/10.1007/s00432-025-06355-y

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06355-y

Keywords: immune checkpoint inhibitors, non-small cell lung cancer, chemoradiotherapy, treatment patterns, tumor recurrence, personalized medicine.

Non-small cell lung cancer remains a leading cause of cancer-related mortality worldwide, with metastatic dissemination to the liver marking a particularly ominous prognosis. Nearly one-fifth of NSCLC patients develop liver metastases, a subset characterized by diminished quantities and impaired activity of effector CD8+ T cells—key players in tumor immune surveillance and destruction. Prior preclinical research has implicated liver metastases as active agents of systemic immune suppression through mechanisms such as the sequestration of neoantigen-specific cytotoxic T lymphocytes followed by their destruction mediated by intrahepatic macrophages. This immune siphoning results in a systemic depletion of effector cells, thereby attenuating the efficacy of immune checkpoint blockade therapies that rely on robust T cell function.

The novel HAMMER-NSCLC trial emerges directly from these insights by testing a hypothesis borne out in animal models: that targeted ablation of liver metastases using SABR can reverse hepatic-mediated systemic immunosuppression and synergize with anti-PD-(L)1 immunotherapy to improve patient outcomes. SABR is a precision radiotherapeutic approach that delivers ablative doses of radiation to defined extracranial targets with millimetric accuracy, minimizing damage to surrounding normal tissue. In the context of liver metastases, SABR’s capability to induce local tumor destruction while potentially modulating the immune milieu renders it an attractive adjunct to systemic immunotherapy.

This multicenter, randomized phase II trial is designed to enroll 68 patients newly diagnosed with metastatic NSCLC who lack actionable mutations in EGFR, ALK, BRAF, or ROS1 genes—thereby focusing on a population primarily reliant on immunotherapy rather than targeted molecular agents. Eligible participants are randomized evenly to receive either the current standard-of-care anti-PD-(L)1-based immunotherapy with or without platinum-based chemotherapy, or the same systemic regimen combined with liver-directed SABR.

A critical design element of HAMMER-NSCLC is its timing of intervention. For the group receiving SABR, the ablation is ideally completed prior to the initiation of immunotherapy, or at the latest before the third cycle commences, ensuring maximum potential for reversing immunosuppression before systemic therapy intensifies. This temporal sequencing is aligned with preclinical evidence suggesting that immediate disruption of liver metastases dampens the hepatic immune sink effect, allowing for the expansion of neoantigen-specific T cells during immunotherapy.

The primary endpoint of the study, progression-free survival (PFS), was chosen to evaluate whether this combinational approach can significantly delay disease progression compared to immunotherapy alone. With a target hazard ratio of 0.6, the trial aims to demonstrate a meaningful clinical benefit, powered at 80% with a one-sided alpha of 10%. Secondary outcomes include evaluating overall survival, hepatic progression rates, and the safety profile of adding SABR to systemic immunotherapy.

This trial’s scientific premise is deeply rooted in the evolving understanding of the tumor-immune microenvironment and the interplay between metastatic niches and systemic immunity. Liver metastases uniquely modulate systemic immunity because of the liver’s intrinsic immunoregulatory functions, which are essential for maintaining tolerance to gut-derived antigens but unfortunately also create a sanctuary for tumor cells. This immunotolerant environment is manipulated by metastases to promote immune evasion, thereby undermining the systemic anti-tumor immune response.

The integration of SABR represents an attempt to convert this immunosuppressive hepatic environment into one that can facilitate immune reinvigoration. SABR-mediated tumor ablation not only physically destroys metastatic deposits but may also precipitate the release of tumor antigens and pro-inflammatory signals, potentially priming systemic antitumor immune responses. This in situ vaccination effect is hypothesized to amplify the efficacy of anti-PD-(L)1 agents, which act by releasing the brakes on exhausted T cells.

If successful, the implications of HAMMER-NSCLC are far-reaching, potentially redefining the standard of care for NSCLC patients with liver metastases. Current immunotherapy regimens achieve remarkable responses in many patients, yet those with hepatic involvement remain an underserved group with limited complete responses and shortened survival. By demonstrating that targeted liver SABR can rescue the immunotherapeutic response in this subgroup, the study could catalyze a paradigm shift toward multidisciplinary treatment strategies combining localized tumor ablation with systemic immunomodulation.

Moreover, the trial will provide critical data on the safety and tolerability of combining liver SABR with anti-PD-(L)1 treatments, addressing concerns about potential additive toxicities such as radiation-induced liver injury or exacerbated immune-related adverse events. This is especially pertinent given the delicate balance of achieving potent anticancer immunity without provoking deleterious systemic immune activation.

Beyond NSCLC, the biological insights gained from HAMMER-NSCLC could illuminate therapeutic avenues in other malignancies where liver metastases drive immunosuppression, such as colorectal and pancreatic cancers. Understanding how hepatic-directed therapies intersect with immunotherapy could foster novel combinatorial regimens boosting systemic antitumor immunity across cancer types.

The trial’s meticulous design incorporates flexibility to enroll patients up to the initiation of the third immunotherapy cycle, increasing accessibility and feasibility across clinical settings. This pragmatic element enhances the potential for real-world applicability and rapid translation of results into clinical practice.

Importantly, the study excludes patients with targetable mutations to preserve a homogeneous cohort reliant on immunotherapy-based treatments. This ensures that observed outcomes can be attributed primarily to the combination of SABR and immune checkpoint blockade, reducing confounding from targeted therapies known to influence disease course distinctly.

The focus on progression-free survival as the primary endpoint underscores the urgency to extend the time during which patients remain free of disease progression, thereby improving quality of life and possibly providing a window for later therapeutic interventions. Secondary endpoints such as overall survival and hepatic progression rates will further elucidate the durability of responses and the specific impact on liver metastases, which often dictate clinical deterioration.

The trial is registered under NCT05657873, reflecting contemporary standards in clinical transparency and rigor. As recruitment proceeds, clinicians and researchers alike await pivotal data that could validate hepatic SABR as a crucial adjunct in immunotherapy protocols.

In an era where precision oncology increasingly hinges on nuanced understanding of tumor-immune interactions within metastatic niches, HAMMER-NSCLC exemplifies a bold translational leap. Should the hypothesis prove correct, this approach could unlock new therapeutic windows for patients whose disease has hitherto been refractory to immune-based strategies, heralding a new chapter in the fight against metastatic lung cancer.

As the oncology community watches closely, the success of HAMMER-NSCLC may inspire analogous investigations integrating localized ablative modalities with systemic immunotherapies, ultimately transforming metastatic cancer from an incurable disease state to a manageable chronic condition through synergistic multimodal treatment.

Subject of Research:
Enhancing immunotherapy efficacy in metastatic non-small cell lung cancer through hepatic stereotactic ablative radiotherapy targeting liver metastases.

Article Title:
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).

Article References:
McMillan, M.T., Reyngold, M., Crane, C.H. et al. A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC). BMC Cancer 25, 1408 (2025). https://doi.org/10.1186/s12885-025-14779-5

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14779-5

The biological underpinnings of ICI resistance are layered and complex, involving both intrinsic tumor factors and adaptive alterations within the tumor microenvironment (TME). Tumor cells can escape immune destruction through a panoply of mechanisms, ranging from genetic and epigenetic modifications that alter antigen presentation and immune recognition to the evolution of immunosuppressive stromal components that blunt effective immune cell infiltration and effector function. Additionally, host-related influences, including dysbiosis of the gut microbiome and organ-specific pathologies, further modulate the landscape of resistance, highlighting the multifactorial nature of immune escape in NSCLC.

Crucially, while the molecular and cellular routes to resistance are diverse, they often converge on a shared endpoint: the establishment of an immunosuppressive TME. This hostile milieu orchestrates a blockade of antitumor immunity, rendering ICIs ineffective despite their initial promise. Thus, current research and therapeutic strategies have increasingly focused on disrupting or reprogramming the immunosuppressive circuitry within the TME to restore effective immune surveillance and cytotoxicity.

Emerging antibody-based modalities constitute a major pillar of these efforts. Innovative constructs such as bispecific antibodies, T cell engagers, and antibody-drug conjugates are designed to simultaneously target multiple immunoregulatory pathways or deliver cytotoxic payloads selectively to malignant cells. These multifunctional biologics aim to circumvent resistance mechanisms by either reinvigorating exhausted T cells or directly eliminating suppressive cell populations within the tumor niche.

Beyond antibodies, small molecule targeted therapies offer additional avenues to counteract resistance. By inhibiting tumor-intrinsic signaling pathways that promote immune evasion or by reshaping the TME through modulation of stromal or myeloid cell functions, these agents may re-sensitize tumors to immune checkpoint blockade. Moreover, combination regimens that integrate targeted inhibitors with ICIs are under active clinical investigation, seeking synergistic effects against refractory NSCLC.

Adoptive cell therapies also hold promise as next-generation immune interventions. Techniques such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) expansion are being refined to enhance specificity, persistence, and tumor homing in solid tumors like NSCLC. These personalized immunotherapies may overcome some intrinsic barriers posed by the tumor and its microenvironment, offering potential salvage options for patients with checkpoint-resistant disease.

Therapeutic cancer vaccines and intratumoral immunotherapies represent additional innovative frontiers. These strategies aim to boost tumor antigen presentation and prime endogenous immune responses directly within the tumor milieu. By localizing immune activation and circumventing systemic immune suppression, they may create focal points of antitumor immunity conducive to durable disease control.

Despite the proliferation of novel therapeutic approaches, the identification and validation of robust predictive biomarkers for immune resistance remain a critical unmet need. Current biomarkers, often derived from sequencing or immunohistochemical analyses, provide incomplete prognostication, reflecting the heterogeneity and dynamic nature of resistance mechanisms. The complexity is compounded by the spatial and temporal variability in tumor and immune cell phenotypes, necessitating longitudinal and multifaceted biomarker strategies.

To effectively navigate this complexity, adaptive, hypothesis-generating clinical trial designs have garnered attention. Such flexible frameworks enable real-time integration of biomarker data and allow brisk incorporation of emerging therapeutic concepts. This iterative approach may accelerate the discovery of effective combination regimens and personalized treatment strategies tailored to the evolving resistance profiles of individual patients.

In parallel, advances in spatial transcriptomics, multiplex immunofluorescence, and single-cell sequencing technologies are shedding light on the intricate cellular interplay within the NSCLC microenvironment. These tools facilitate high-resolution mapping of immune and stromal components, revealing potential vulnerabilities and resistance drivers that may be therapeutically exploitable. Integrating these molecular insights into clinical practice remains a critical translational challenge.

Furthermore, the role of the gut microbiome in shaping systemic immunity and modulating responses to ICIs has emerged as a fascinating area of study. Dysbiosis—disruption of the normally balanced microbial communities—can negatively impact immune competence and foster resistance. Therapeutic manipulation of the microbiome through probiotics, antibiotics, or fecal microbiota transplantation is under exploration as an adjunct to immunotherapy.

Organ-specific microenvironments, such as those in the brain or liver where metastatic lesions commonly reside, also impose unique immunological constraints. Understanding how these sites influence immune cell trafficking and function will be pivotal in designing therapies that overcome tissue-specific barriers to checkpoint inhibitor efficacy.

Taken together, these insights underscore a paradigm shift in NSCLC treatment from monolithic checkpoint blockade to sophisticated, multi-modal strategies tailored to dismantle the immunosuppressive fortress encasing resistant tumors. Interdisciplinary collaboration among oncologists, immunologists, molecular biologists, and bioinformaticians is crucial in accelerating this progress.

While substantial challenges persist, the trajectory of research efforts offers a cautiously optimistic outlook. Early-phase clinical trials of combination regimens and novel immune-activating platforms have reported encouraging signals of efficacy. Continued refinement of therapeutic approaches and biomarker-guided patient selection promise to enhance response rates and extend survival benefits beyond what was once achievable.

As the field moves forward, a comprehensive understanding of the dynamic interplay between tumor biology, the immune milieu, and host factors will be essential. This holistic perspective will enable the design of rational interventions to preempt, delay, or reverse resistance to ICIs in NSCLC, transforming a currently intractable problem into a manageable clinical reality.

In summary, the battle against immune checkpoint inhibitor resistance in NSCLC is entering a new chapter defined by scientific ingenuity and clinical innovation. By harnessing emerging technologies, embracing adaptive trial designs, and integrating multidimensional biomarkers, researchers are steadily unraveling the complexities that have long thwarted durable immunotherapeutic success. The coming years may well witness the translation of these advances into tangible improvements in patient care worldwide.

Subject of Research: Resistance to immune-checkpoint inhibitors in advanced non-small-cell lung cancer and emerging therapeutic strategies.

Article Title: Treatment of NSCLC after chemoimmunotherapy — are we making headway?

Article References: Reck, M., Frost, N., Peters, S. et al. Treatment of NSCLC after chemoimmunotherapy — are we making headway?. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01061-7

Image Credits: AI Generated

DOI: 10.1038/s41571-025-01061-7

Keywords: non-small-cell lung cancer, immune-checkpoint inhibitors, immune resistance, tumor microenvironment, bispecific antibodies, T cell engagers, adoptive cell therapy, therapeutic vaccines, biomarker-driven studies

Small cell lung cancer, particularly in its extensive-stage form, notoriously portends a poor prognosis with limited long-term survival despite initial responsiveness to chemotherapy. Over recent years, the integration of immune checkpoint inhibitors with chemotherapy has moderately improved outcomes, yet the role of adjunctive radiotherapy—especially the timing of its delivery—has remained ambiguous. Wang and colleagues embarked on a comprehensive real-world investigation to discern whether early radiotherapy, administered before disease progression, could further enhance survival metrics in ES-SCLC patients receiving first-line chemo-immunotherapy.

The study enrolled 375 patients diagnosed with ES-SCLC between August 2018 and October 2023, a cohort reflective of contemporary treatment practices and demographic diversity. Patients were stratified into two primary groups based on whether they received early radiotherapy prior to disease progression or were managed with salvage or no radiotherapy subsequently. To minimize confounding biases and ensure comparability, the researchers applied rigorous propensity score matching at a 1:1 ratio, meticulously balancing baseline clinical characteristics between cohorts for robust outcome analysis.

Results were striking: the Early Radiotherapy (Early RT) group exhibited a median progression-free survival (PFS) of 11.4 months, nearly doubling that of the Salvage and Non-Radiotherapy (S&N RT) group, which recorded a median PFS of just 6.1 months. This corresponded to a hazard ratio (HR) of 0.59, indicating a 41% reduction in the risk of cancer progression or death for those receiving early radiotherapy, with the difference achieving strong statistical significance (p < 0.001). Such a pronounced improvement underscores the potential of early radiotherapy to delay disease advancement when synergized with chemo-immunotherapeutic agents.

Even more compelling was the observed improvement in overall survival (OS) within the Early RT cohort. Median OS extended to 23.8 months compared to 18.0 months in the S&N RT group, equating to a 50% decrease in mortality risk (HR = 0.50; p = 0.004). Notably, this survival benefit endured after meticulous adjustment via propensity score matching, affirming the robustness of the association. These findings provide persuasive evidence that timely radiotherapeutic intervention, integrated with systemic therapy, can meaningfully prolong life expectancy in this difficult-to-treat population.

Further subgroup analyses refined our understanding of radiotherapy’s role: patients who underwent salvage radiotherapy—delivered only after documented disease progression—showed no significant survival advantage over those who did not receive radiotherapy at all. Direct comparison between early and salvage radiotherapy groups highlighted a statistically significant survival improvement favoring the early administration approach (p = 0.028). This distinction suggests that radiotherapy’s therapeutic window is critical and that delayed intervention may miss the opportunity for maximum disease control.

Safety profiles documented within this cohort added further reassurance. Although the combination of radiotherapy with chemo-immunotherapy raises concerns regarding additive toxicities, the observed adverse events remained within tolerable limits, with no unexpected safety signals reported. This favorable risk-benefit ratio strengthens the case for early radiotherapy’s inclusion in standard treatment protocols, pending validation from prospective clinical trials.

The mechanistic rationale for these observations likely stems from the dual capacity of radiotherapy to achieve locoregional disease control and potentiate systemic immune responses. Early radiotherapy may reduce tumor burden, thereby decreasing the immunosuppressive milieu and enhancing immune checkpoint inhibitors’ effectiveness. By contrast, salvage radiotherapy administered after systemic progression may encounter resistant tumor clones and diminished host immunity, curtailing therapeutic efficacy.

This study pioneers a vital shift in the therapeutic sequencing of ES-SCLC treatments. Traditionally, radiotherapy has been considered a later-stage salvage modality, primarily reserved for symptom palliation or isolated progression. Wang et al.’s work challenges that orthodoxy, advocating for a proactive, integrated strategy that leverages radiotherapy’s synergistic synergy when introduced early into the treatment continuum.

Importantly, the real-world nature of this study—encompassing heterogeneous patient populations and treatment settings—enhances the generalizability of the findings compared to controlled clinical trial environments. Such data are invaluable for guiding everyday clinical decision-making, enabling oncologists to tailor treatment intensity and timing with greater confidence.

Yet, while retrospective and observational evidence is compelling, prospective randomized controlled trials remain necessary to definitively confirm early radiotherapy’s survival benefit and to refine patient selection criteria. It will be crucial to understand which subsets of ES-SCLC patients derive maximal advantage, identify optimal radiation dosing and scheduling, and elucidate potential biomarkers predicting response.

Another vital consideration is the interplay between radiotherapy and emerging systemic agents beyond currently approved immune checkpoint inhibitors. Novel immunomodulatory drugs, targeted therapies, and agents modifying the tumor microenvironment might further interact with radiotherapy’s effects, potentially magnifying therapeutic gain. Future research should explore these combinations to maximize clinical benefit.

In sum, this landmark study by Wang and colleagues resonates as a call to action within oncology and radiation oncology communities. Integration of early radiotherapy into first-line chemo-immunotherapy regimens may redefine standard care for ES-SCLC, transforming a historically grim prognosis into one of hope and extended survival. As the oncology field embraces precision medicine and multimodal approaches, timing radiotherapy early could emerge as a cornerstone for establishing durable remission in this challenging disease.

Clinicians now face an exciting moment: armed with these findings, they can reconsider treatment algorithms and advocate for early multispecialty collaboration, ensuring that radiotherapy is neither an afterthought nor a salvage recourse but a frontline component synergizing with systemic therapies. These shifts may ultimately translate into tangible gains in survival and quality of life for thousands of patients facing extensive-stage small cell lung cancer globally.

As a next crucial step, ongoing and future randomized studies must explore not only survival endpoints but also quality-of-life measures, toxicity profiles, and cost-effectiveness to comprehensively define early radiotherapy’s role within the evolving landscape of ES-SCLC treatment. The oncology community eagerly anticipates results that may unlock greater therapeutic precision and herald a new era of hope for patients afflicted by this aggressive malignancy.

Until then, the findings disseminated by Wang and the BMC Cancer team offer both urgent guidance and inspiring insight, heralding a new chapter underscoring the importance of timing, integration, and innovation in lung cancer therapy. This research marks a milestone in shifting radiotherapy from a salvage tool to a proactive agent for survival enhancement in extensive-stage small cell lung cancer management.

Subject of Research: Early radiotherapy efficacy in extensive-stage small cell lung cancer patients receiving first-line chemo-immunotherapy.

Article Title: Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.

Article References:

Wang, Y., Su, X., Jia, J. et al. Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.
BMC Cancer 25, 1012 (2025). https://doi.org/10.1186/s12885-025-14417-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14417-0

Immune checkpoint inhibitors work by blocking proteins such as PD-1, PD-L1, or CTLA-4, which cancer cells exploit to evade immune detection. By inhibiting these checkpoints, ICIs effectively ‘release the brakes’ on immune cells, enabling them to attack tumor cells more aggressively. Despite their efficacy, this mechanism can be a double-edged sword, eliciting inflammatory responses affecting organs including the lungs, colon, and liver. In clinical practice, the onset of irAEs introduces a complex clinical decision-making process, balancing toxicity management with continuing potentially life-saving therapy. The study led by Dr. Mark Awad and Federica Pecci meticulously explored this balance and the clinical trajectories following therapy cessation.

Drawing from a robust, multi-institutional cohort encompassing 2,794 NSCLC patients treated with ICIs as monotherapy or in combination with other treatments, approximately 10% who discontinued ICIs due to irAEs were evaluated for their subsequent clinical outcomes. Astonishingly, the median progression-free survival (PFS) following discontinuation was 12.7 months, while the overall survival (OS) extended to a median of 43.7 months. These findings illuminate the potential for a durable anticancer effect that persists beyond active treatment, a concept that challenges conventional paradigms requiring continuous therapy for disease control.

A notable aspect of the study was its stratification of patients based on treatment duration prior to discontinuation. Patients treated for less than three months before stopping immunotherapy had a median post-discontinuation PFS of 6.2 months, whereas those treated between three and six months, and more than six months had PFS durations of 13.9 and 25.8 months, respectively. Overall survival followed a similar trend, with median OS of 21.7 months, 42.7 months, and 86.9 months corresponding to these treatment intervals. These data suggest that longer exposure before discontinuation correlates with improved long-term outcomes, highlighting a possible dose-response effect even in the context of treatment cessation due to toxicity.

A deeper multivariable analysis identified several clinical and pathological factors associated with prolonged disease control after ICI discontinuation. High PD-L1 expression—a biomarker predicting responsiveness to ICIs—alongside achieving a complete or partial response to therapy, and longer duration of treatment before discontinuation, emerged as predictors of extended progression-free survival. Similarly, nonsquamous histology, robust tumor response, and extended treatment duration were linked with improved overall survival rates. These insights offer oncologists valuable parameters to identify patients who may safely discontinue immunotherapy without immediate risk of progression.

Intriguingly, the study also addressed the impact of managing irAEs with immunosuppressants such as corticosteroids. Historically, concern has prevailed that suppressing the immune system might diminish the efficacy of immunotherapy and compromise anticancer effects. However, the analysis revealed no significant difference in PFS or OS between patients who received steroids or other immunosuppressive agents and those who did not. This finding carries substantial clinical implications, reassuring providers and patients that necessary interventions for irAEs may not undermine long-term cancer control.

The implications of these findings extend beyond the clinical metrics, touching upon the quality of life and patient decision-making. Immune-related toxicities can considerably impair well-being, often forcing patients into a difficult crossroad where continuing treatment may not be feasible or desirable. The reassurance that durable responses can be sustained post-discontinuation empowers both clinicians and patients, facilitating more personalized treatment approaches that weigh toxicities against survival benefits in a nuanced fashion.

From a mechanistic standpoint, the persistently durable responses observed may be explained by the enduring activation of immunological memory even after cessation of checkpoint inhibition. Immune system priming and clonal expansion of tumor-reactive T cells might sustain antitumor activity, but this hypothesis requires further research. The study’s retrospective design and potential biases, such as the enrichment of long-term responders in longer treatment durations, are acknowledged limitations. Nonetheless, the authors employed landmark analyses and multivariable Cox models to reduce confounding factors and bolster the robustness of their conclusions.

Expert commentary by Dr. Pecci emphasized the study’s role as a clinical resource in guiding decisions about treatment discontinuation in the context of irAEs. The work aids clinicians in navigating the grey zones between necessary cessation for severe toxicity and cautiously continuing therapy in moderate cases. By identifying prognostic markers, physicians can tailor counseling and follow-up intensities, ultimately refining care in this complicated therapeutic landscape.

This research aligns with an evolving understanding of cancer immunotherapy, where the durability of responses transcends the duration of active treatment. It challenges the traditional dogma of indefinite therapy until progression or unacceptable toxicity, inviting a paradigm shift towards strategic treatment breaks when warranted. Future prospective studies are warranted to validate these findings and explore the molecular underpinnings of prolonged tumor control post-ICI discontinuation.

Funding from the National Institutes of Health supported this collaborative endeavor, with disclosures transparently reported. The lead investigator, Dr. Awad, noted extensive consulting relationships and institutional funding from multiple pharmaceutical entities involved in immunotherapy development, reflecting a well-connected research milieu. Federica Pecci declared no conflicts of interest, underpinning the integrity of the study’s findings.

This study, published in the authoritative journal Clinical Cancer Research, stands to influence treatment guidelines and patient management strategies in NSCLC immunotherapy. By elucidating the factors that predict extended survival and disease control after immunotherapy discontinuation due to irAEs, it empowers clinicians to make more informed, personalized decisions in a rapidly advancing field.

Subject of Research: Long-term outcomes and predictors of disease control in NSCLC patients after discontinuation of immune checkpoint inhibitors due to immune-related adverse events.

Article Title: Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer

News Publication Date: 18-Apr-2025

Web References:
https://doi.org/10.1158/1078-0432.CCR-24-2990

Keywords: Cancer immunotherapy, immune checkpoint inhibitors, non-small cell lung cancer, immune-related adverse events, disease progression, progression-free survival, overall survival, PD-L1 expression, immunosuppression, treatment discontinuation